Opinion Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry. While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry…
Opinion Holmusk’s Nawal Roy highlights the increasing recognition of the value of real-world evidence (RWE) by both innovative pharma companies and drug regulators and its potential to increase market capture and profitability. RWE has the potential to expand the market size of a disease and accelerate market capture of a…
See our Cookie Privacy Policy Here
